FDA updates sotatercept-csrk label with HYPERION data, showing earlier use cuts PAH clinical worsening risk 76% alongside background therapy.
News|Articles|December 31, 2006
Keep Patients From Getting Lost in Translation
Patients who don’t speak Englishoften bring a translator to their firstvisit but not to subsequent ones.
Advertisement
Patients who don't speak Englishoften bring a translator to their firstvisit but not to subsequent ones. Tellthe patient to carry a cellular phoneon future visits and to make sure atranslator is available to call. This ismore convenient than using the officephone.
-- Sarita Salzberg, MD
Columbus, Ohio
Advertisement
Related to this article
A US laboratory study found that 29.5% of patients with Lyme antibodies were seropositive for at least 1 other tick-borne pathogen.
Lumateperone reduced acute mania symptoms by day 3 in a phase 3 bipolar 1 trial, according to Johnson & Johnson.
Endocrine Society statement highlights key research gaps on obesity drugs—who benefits, long-term dosing, safety, and measuring success beyond weight loss.
Finerenone wins FDA clearance for type 1 diabetes–related CKD, lowering albuminuria in FINE-ONE and opening a long-awaited treatment path.
New American Society of Hematology guidelines raise ferritin cutoffs to catch iron deficiency sooner, including pregnancy and inflammation, and add TSAT for clearer diagnosis.
The US FDA cleared a novel insulin patch pump that can be used for up to 3 days with an additional 12-hour grace period in persons with diabetes.
Takeda’s oral TYK2 inhibitor showed rapid skin clearance in phase 3 psoriasis trials as FDA fast-tracks review; decision expected early 2027.
Advertisement
Advertisement
Trending on Patient Care Online
1
Lumateperone Reduces Acute Mania Symptoms in Phase 3 Bipolar I Trial
2
FDA Approves Sotatercept-csrk Label Update for Newly Diagnosed PAH
3
Endocrine Society Obesity Statement Calls for Goals Beyond Weight Loss
4
Clinical Inertia and Poor Measurement Technique Undermine BP Control
5